Navigation Links
New target for cancer therapy identified, preclinical study shows

New York, NY -- Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors. Called tryptophan 2,3-dioxygenase or TDO, the enzyme works by depriving immune cells of tryptophan, an amino acid essential to their activity. TDO is produced by a significant number of human tumors. Scientists also show that blocking TDO activity with a novel TDO inhibitor promotes tumor rejection in mice. The study findings were published online today in the January 30 issue of the Proceedings of the National Academy of Sciences (PNAS).

Cancer immunotherapy leveraging the body's own immune system to attack and destroy tumors is emerging as a promising method for cancer treatment. Clinical testing of several immunotherapeutic approaches has shown variable success. Tumors often develop survival mechanisms to prevent the attack from the immune system. Researchers are now looking to evaluate the mechanisms that enable these tumors to escape detection by the immune system.

Previously, Brussels scientists from LICR and the de Duve Institute at the Universit catholique de Louvain (UCL) studied one enzyme that proved to do just that. It is known as indoleamine 2,3 dioxygenase or IDO1 for short. IDO1 is expressed in many cancers, including prostate, colon, pancreas and cervical tumors. IDO1 blocks the immune system's ability to reject those tumors, by depriving immune cells of tryptophan. In the PNAS study released today, the same Belgian researchers have shown that TDO is also expressed in various human tumors and degrades tryptophan in a similar manner. Tumors expressing TDO include bladder and liver cancers, as well as melanomas.

"Little is known about the TDO enzyme and its ability to trick the immune system and prevent it from destroying deadly tumors. Our research is the first to explore this relationship," said study lead investigator, Benoit J. Van den Eynde, M.D., Ph.D., Brussels Branch Director at LICR.

The group studied a series of 104 human tumor lines of different types to confirm the activity of TDO in tumor cells. They learned that 20 tumors expressed TDO only, 17 others expressed IDO1 only and 16 expressed both. The findings suggest that TDO and IDO1 enzymes represent complementary cancer immunotherapy targets, which if blocked could potentially impact 51% of all tumors.

Demonstrating TDO Expression and Its Role in Thwarting Immune Attack

Using a validated mouse tumor model, researchers established that TDO expression caused tumor cells to resist immune rejection. They first vaccinated the mice with an antigen that caused them to reject the tumor. Then they injected TDO-expressing tumor cells into the immunized mice. Researchers found that immunized mice no longer rejected the TDO-expressing tumors. This demonstrated that the presence of TDO prevented the immune system from attacking tumors.

In collaboration with scientists from the University of Namur (Belgium), the team then developed an active compound to inhibit TDO enzymatic activity. "Our study showed quite beautifully that the TDO inhibitor restored the ability of mice to reject tumors despite the presence of TDO in tumor cells," said Dr. Van den Eynde.

Research recently published in the October 6, 2011 issue of Nature (Opitz, C.A. et al.) validates today's study results by showing that TDO expression in human glioblastomas promotes tumor progression.

Toward Clinical Development of a TDO-inhibitor

The research team is moving forward to validate TDO inhibition in other preclinical models. Working closely with LICR colleagues in San Diego, the team will also conduct high-throughput screening to find a more stable TDO-inhibitor compound that can be advanced in clinical testing.

LICR plans, conducts, administers, and sponsors its own clinical trials as part of its technology development process. This process allows basic investigations to continue into early stage clinical evaluation of a new therapy, and makes the clinic an essential arm of the research enterprise.

"We will continue to search for inhibitors of TDO, an important new clinical target," confirmed Jonathan Skipper, Ph.D., Executive Director, Technology Development at LICR. "LICR intends to license its discovery to a new commercial enterprise in the near future."

Contact: Rachel Steinhardt
Ludwig Institute for Cancer Research

Related medicine news :

1. Researchers Spot Potential Bile Duct Cancer Drug Targets
2. New therapeutic target to combat liver cancer discovered
3. Protein in the brain could be a key target in controlling Alzheimers
4. Rowley to receive Japan Prize for her role in the development of targeted cancer therapy
5. NIH grant targets inflammation in link between obesity and disease
6. U. of Nebraska to lead $25 million project targeting E. coli threat
7. Alcohol Targets Brain Reward Centers in Heavy Drinkers
8. Gene identified as a new target for treatment of aggressive childhood eye tumor
9. Unexpected discovery opens up new opportunities for targeting cancer
10. Researchers discover protein that may represent new target for treating type 1 diabetes
11. Targeted therapy extends progression-free survival of patients with advanced ovarian cancer
Post Your Comments:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
Breaking Medicine Technology: